全球抗癌药物市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

全球抗癌药物市场需求预计将从 2023 年的 1,576.1 亿美元增至 2032 年的近 3,902.7 亿美元，2024-2032 年研究期间复合CAGR为 10.6%。

抗癌药物，也称为化疗或抗癌药物，是旨在靶向并破坏体内癌细胞的药物。它们是癌症治疗的重要组成部分，通常与手术、放射治疗或免疫疗法等其他治疗方法结合使用。

市场动态

在多种因素的推动下，抗癌药物市场正经历显着成长。主要催化剂是全球癌症发生率不断上升，需要有效和先进的治疗方案。药物开发的技术进步，特别是标靶疗法和免疫疗法的出现，已经改变了癌症治疗，促进了对专门针对癌细胞的创新药物的需求。鑑于老年人癌症盛行率较高，全球人口老化对市场扩张做出了重大贡献。提高意识和早期癌症检测也发挥关键作用，使抗癌药物的治疗更有效。政府对癌症研究的措施和投资进一步推动市场成长，重点是提高癌症治疗的可近性。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球抗癌药物市场的各个细分市场进行了包容性评估。抗癌药物产业的成长和趋势为这项研究提供了整体方法。

市场区隔

抗癌药物市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

依药物类型

• 细胞毒性药物（烷基化 Agerits、抗代谢药等）
• 标靶药物（单抗体、酪胺酸激酶抑制剂等）
• 荷尔蒙药物

按治疗类型

• 化疗
• 标靶治疗
• 免疫疗法
• 其他的

按癌症类型

• 肺癌
• 乳癌
• 白血病
• 大肠直肠癌
• 其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲抗癌药物市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。抗癌药物市场的主要参与者包括安进、武田製药有限公司、礼来公司、罗氏公司、诺华公司、辉瑞公司、拜耳公司、默克公司、新基公司。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法论
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：抗癌药物 - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业动态
• 波特五力分析
• 市场吸引力分析
  • 按药物类型分類的市场吸引力分析
  • 按治疗类型分類的市场吸引力分析
  • 按癌症类型分類的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料厂商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第 5 章：全球抗癌药物市场分析：依药物类型

• 按药物类型概述
• 历史和预测数据
• 依药物类型分析
• 细胞毒性药物（烷基化 Agerits、抗代谢药等）
• 标靶药物（单抗体、酪胺酸激酶抑制剂等）
• 荷尔蒙药物

第 6 章：全球抗癌药物市场分析：依治疗类型

• 按治疗类型概述
• 历史和预测数据
• 依治疗类型分析
• 化疗
• 标靶治疗
• 免疫疗法
• 其他的

第 7 章：全球抗癌药物市场分析：按癌症类型

• 按癌症类型概述
• 历史和预测数据
• 按癌症类型分析
• 肺癌
• 乳癌
• 白血病
• 大肠直肠癌
• 其他的

第 8 章：全球抗癌药物市场分析：依地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概览、历史与预测资料销售分析
  • 北美按细分市场销售分析
  • 北美按国家销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史与预测资料销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概览、历史与预测资料销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区国家/地区销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 东南亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概览、历史与预测资料销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概览、历史与预测资料销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 9 章：抗癌药物公司的竞争格局

• 抗癌药物市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 10 章：公司简介

• 公司股份分析
• 市场集中度
• Amgen Inc
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Takeda Pharmaceutical Company Limited
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Eli Lilly and Company
• 公司简介
• 公司收入
• 产品
• 最近的发展
• F. Hoffmann-La Roche Ltd.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Novartis AG
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Pfizer Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Bayer AG
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Merck & Co Inc
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Celgene Corporation
• 公司简介
• 公司收入
• 产品
• 最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

The global demand for Anticancer Drugs Market is presumed to reach the market size of nearly USD 390.27 BN by 2032 from USD 157.61 BN in 2023 with a CAGR of 10.6% under the study period 2024 - 2032.

Anticancer drugs, also known as chemotherapy or cancer-fighting drugs, are medications designed to target and destroy cancer cells in the body. They are a crucial component of cancer treatment, often used in combination with other therapeutic approaches like surgery, radiation therapy, or immunotherapy.

MARKET DYNAMICS

The Anticancer drugs market is experiencing significant growth driven by multiple factors. A primary catalyst is the escalating global incidence of cancer, necessitating effective and advanced treatment options. Technological advancements in drug development, particularly the emergence of targeted therapies and immunotherapies, have transformed cancer treatment, fostering a demand for innovative drugs that specifically target cancer cells. The aging global population contributes substantially to market expansion, given the higher prevalence of cancer in older individuals. Increased awareness and early cancer detection also play a pivotal role, enabling more effective treatment with anticancer drugs. Government initiatives and investments in cancer research further drive market growth, with a focus on improving accessibility to cancer treatment.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of anticancer drugs. The growth and trends of anticancer drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the anticancer drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

• Cytotoxic Drugs (Alkylating Agerits, Antimetabolites, Others)
• Targeted Drugs (Monodional Antibodies, Tyrosine Kinase Inhibitors, Others)
• Hormonal Drugs

By Therapy Type

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others

By Cancer Type

• Lung Cancer
• Breast Cancer
• Leukemia
• Colorectal Cancer
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Anticancer Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Anticancer Drugs market include Amgen Inc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Bayer AG, Merck & Co Inc, Celgene Corporation. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . ANTICANCER DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Type
  • 3.7.2 Market Attractiveness Analysis By Therapy Type
  • 3.7.3 Market Attractiveness Analysis By Cancer Type
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ANTICANCER DRUGS MARKET ANALYSIS BY DRUG TYPE

• 5.1 Overview by Drug Type
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Drug Type
• 5.4 Cytotoxic Drugs (Alkylating Agerits, Antimetabolites, Others) Historic and Forecast Sales by Regions
• 5.5 Targeted Drugs (Monodional Antibodies, Tyrosine Kinase Inhibitors, Others) Historic and Forecast Sales by Regions
• 5.6 Hormonal Drugs Historic and Forecast Sales by Regions

6 . GLOBAL ANTICANCER DRUGS MARKET ANALYSIS BY THERAPY TYPE

• 6.1 Overview by Therapy Type
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Therapy Type
• 6.4 Chemotherapy Historic and Forecast Sales by Regions
• 6.5 Targeted Therapy Historic and Forecast Sales by Regions
• 6.6 Immunotherapy Historic and Forecast Sales by Regions
• 6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL ANTICANCER DRUGS MARKET ANALYSIS BY CANCER TYPE

• 7.1 Overview by Cancer Type
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Cancer Type
• 7.4 Lung Cancer Historic and Forecast Sales by Regions
• 7.5 Breast Cancer Historic and Forecast Sales by Regions
• 7.6 Leukemia Historic and Forecast Sales by Regions
• 7.7 Colorectal Cancer Historic and Forecast Sales by Regions
• 7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL ANTICANCER DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE ANTICANCER DRUGS COMPANIES

• 9.1. Anticancer Drugs Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF ANTICANCER DRUGS INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Amgen Inc
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. Takeda Pharmaceutical Company Limited
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. Eli Lilly and Company
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. F. Hoffmann-La Roche Ltd.
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. Novartis AG
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. Pfizer Inc.
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. Bayer AG
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. Merck & Co Inc
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. Celgene Corporation
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Drug Type (USD MN)
• Cytotoxic Drugs (Alkylating Agerits, Antimetabolites, Others) Market Sales by Geography (USD MN)
• Targeted Drugs (Monodional Antibodies, Tyrosine Kinase Inhibitors, Others) Market Sales by Geography (USD MN)
• Hormonal Drugs Market Sales by Geography (USD MN)
• Analysis Market by Therapy Type (USD MN)
• Chemotherapy Market Sales by Geography (USD MN)
• Targeted Therapy Market Sales by Geography (USD MN)
• Immunotherapy Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis by Cancer Type (USD MN)
• Lung Cancer Market Sales by Geography (USD MN)
• Breast Cancer Market Sales by Geography (USD MN)
• Leukemia Market Sales by Geography (USD MN)
• Colorectal Cancer Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Anticancer Drugs Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Anticancer Drugs Report
• Market Research Process
• Market Research Methodology
• Global Anticancer Drugs Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Drug Type
• Market Attractiveness Analysis by Therapy Type
• Market Attractiveness Analysis by Cancer Type
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Drug Type (USD MN)
• Cytotoxic Drugs (Alkylating Agerits, Antimetabolites, Others) Market Sales by Geography (USD MN)
• Targeted Drugs (Monodional Antibodies, Tyrosine Kinase Inhibitors, Others) Market Sales by Geography (USD MN)
• Hormonal Drugs Market Sales by Geography (USD MN)
• Global Market Analysis by Therapy Type (USD MN)
• Chemotherapy Market Sales by Geography (USD MN)
• Targeted Therapy Market Sales by Geography (USD MN)
• Immunotherapy Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by Cancer Type (USD MN)
• Lung Cancer Market Sales by Geography (USD MN)
• Breast Cancer Market Sales by Geography (USD MN)
• Leukemia Market Sales by Geography (USD MN)
• Colorectal Cancer Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.